Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Key takeaways: Less than 10% of adults receiving tirzepatide in clinical trials reported a serious adverse event. Gastrointestinal adverse events were common and increased with tirzepatide dosage.

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

Studies were included if they were clinical- or randomized controlled trials investigating the performance of Tirzepatide against insulin in any of the following outcomes – Body weight, fasting ...

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

In a clinical trial, participants who took a higher dosage of Tirzepatide lost up to 22.5% of their body weight, or about 52 pounds, over the course of 72 weeks.

A phase 3 clinical trial of tirzepatide, sold as Mounjaro, has demonstrated that if taken after an initial weight loss brought about by diet and lifestyle changes, the drug can lead to significant ...

Preliminary data from a large Phase 3 clinical trial is offering promising signs for a new anti-obesity drug. Called tirzepatide, the drug helped overweight and obese participants lose up to 22.5 ...

Tirzepatide, a weekly injectable that rivals celebrity-favorite Wegovy, is one step closer to approval for weight loss by the Food and Drug Administration after its latest clinical trial showed ...

In real-world cohort, percentage weight reduction at 1 year was 3.6%, 6.8%, and 11.9% with early and late discontinuation and nondiscontinuation, respectively.